New drug compounds target inflammatory pathway linked to immune diseases

Researchers have identified a new class of inhibitors that block a key step in leukotriene production, a major driver of inflammatory immune responses. The finding could unlock treatment options for conditions like asthma and autoimmune disorders, expanding the addressable market for anti-inflammatory therapeutics beyond current standard therapies.

Originaltitel: Modulation of the 5-Lipoxygenase Pathway by Chalcogen-Containing Inhibitors of Leukotriene A₄ Hydrolase